FACTSHEET

INTRODUCING SCANDION ONCOLOGY A/S

SUMMARY

Scandion Oncology is based on a merger of ion channel technology from Saniona AB (www.saniona.com) and cancer research technologies and inventions from University of Copenhagen. The company was legally founded April 2017. The founders are Saniona AB (51%) and Nils Brünner, Jan Stenvang and Kim Arvid Nielsen (49%).
Scandion Oncology will address one of the most important problems in modern oncology, being treatment of cancers that have developed resistance to anti-cancer therapy. With approximately 14 mill new cancer cases worldwide in 2014 and an estimated 40% risk of developing drug resistance, the business potential for an effective add-on drug to standard chemotherapy is expected to reach that of a blockbuster.

FOUNDED 2017

Address
Scandion Oncology A/S
COBIS,
Ole Maaløes Vej 3
DK – 2200 Copenhagen
Phone: +45 26144708
www.scandiononcology.com

CHALLENGE IN ONCOLOGY

A critical problem in oncology is drug resistance. Although many cancer patients initially benefit from anti-cancer treatment, a large proportion will develop resistance against the used drugs, a feature that prohibits successful treatment of cancer diseases.

OUR MISSION

Scandion Oncology A/S has a unique mission: To develop drugs that specifically target drug resistance mechanisms with an aim to extend survival of cancer patients and at the same time to improve patient quality of life.

INVESTMENT

It is our intention to raise 25 million SEK in a Company listing on Spotlight (former AktieTorget), Sweden or Denmark, in October 2018. The 25 million SEK will be used to bring our lead product SCO-101 through clinical phase IIa studies. Based on a positive result of these studies we will raise additional funds through an emission to fund the clinical phase IIb studies.
Scandion Oncology A/S current pre-money valuation is 42 million SEK.

Why invest in Scandion Oncology:

- High potential return on investment with potential liquidity event in connection with a listing on Spotlight in October 2018
- Fast and cost-efficient track to result with blockbuster potential of +4 billion Euro in sales
- Successful completion achieved of four clinical phase I trials for SCO-101 showing SCO-101 as an oral drug to be safe and only demonstrating limited toxicity
- High medical need which is currently not addressed in the market
- Solid patent portfolio
- SCO-101 is intended to be used in several cancer indications
- Experienced management and Board of Directors with strong Advisory Board

PRODUCTS

Our lead product, SCO-101 is an oral compound that in in vitro and in in vivo studies, enhances the effects of standard anti-cancer treatment when given in combination and to reverse several types of drug resistance of cancer cells. SCO-101 has already successfully passed pre-clinical and 4 different phase I studies. Additional drug production is ongoing at Cambrex Sweden.

Further, we have a compelling pipeline in pre-clinical trial phase: Our development compound SCO-201, has been demonstrated to reverse drug resistance in in vitro settings and pharmacokinetic data have been generated in mice after oral administration. SCO-201 will be developed in parallel to SCO-101. In addition, we have 800 analogs of SCO-101.

DEVELOPMENT PLANS

The goal is to bring our first compound SCO-101 through clinical proof-of-concept phase II studies. Scandion Oncology A/S will initially conduct two clinical run-in phase IIa studies with metastatic breast cancer and metastatic colorectal cancer patients in which patients are exposed to combinations of standard dose of anti-cancer treatment and increasing doses of SCO-101. The main objective of the phase IIa is to evaluate safety when co-administering SCO-101 with standard anti-cancer drugs. These phase IIa studies are expected to take 6-9 months and will be kicked off in H2 2019.
Based on successful completion of the two clinical phase IIa trials, we will bring SCO-101 into two phase IIb studies in combination with standard anti-cancer drugs to obtain proof-of-concept in metastatic drug-resistant breast- and colorectal cancer patients. The clinical phase IIb studies are expected to take an additional 12- 15 and each including between 15 and 25 patients.

.

SCANDION ONCOLOGY

FACTSHEET

MANAGEMENT

NILS BRÜNNER MD, DMSc,
Professor Founder & CEO

MD from University of Copenhagen and trained in Medical Oncology. Professor since 2002 at the University of Copenhagen. Since 2013 Head of Unit for Translational Cancer Research at the Danish Cancer Society. He is author of more than 370 publications, most of which deals with translational cancer research on breast cancer or colorectal cancer. Nils Brünner has more than 10 years' experience serving as CEO and CMO (WntResearch AB), CSO (Oncology Venture A/S) where he is co-founder and member of the SAB in several biotech companies.

JAN STENVANG, PhD.
Founder & CSO

Associate Professor since 2013 at the University of Copenhagen. He earned his MSc degree in University of Southern Denmark. Jan Stenvang has a PhD from the University of Copenhagen, conducted at the Danish Cancer Society on gene regulation and anti-estrogen resistant breast cancer. He is author of 68 publications, the majority focusing on translational cancer research, biomarkers and drug resistance.

CARIT ANDERSEN
Cand. Merc, CFO

Educated as Cand. Merc. and founder of Decisionconsult A/S. He has previously served as CFO at AstraZeneca A/S and Serendex. Furthermore, he has been in several BoDs and possess ample experience form both private industry and public partnering. Carit Andersens expertise includes strategy, budgeting and project management.

SCANDION ONCOLOGY

SCREENING PLATFORM

In parallel to our development activities, Scandion Oncology A/S is exploiting the drug resistant cancer cell platform (DEN50-R) developed by the founders at University of Copenhagen, to find new potential clinical drug combinations with each of SCO-101 and SCO-201 and to identify companion diagnostics (biomarkers) for the Scandion Oncology A/S drugs to be used to select the right patients for the clinical trials.

MARKET SIZE/POTENTIAL

Extensive and externally validated market studies conclude that 180.000 patients across 6 key markets can potentially benefit from the treatment, suggesting an annual peak sales volume in excess of 4 billion Euros for SCO-101 when only including metastatic colon and breast cancer.
SCO-101 and SCO-201 can potentially be used in several other cancer indications which will significantly expand the market potential.
Scandion Oncology has recently identified a novel non-cancer indication for SCO-101 and its analogs. This indication could be as large as the cancer indication.

BOARD OF DIRECTORS AND SCIENTIFIC COMMITTEE

The Board of Directors includes Professional Board member **Jørgen Bardenfleth** (Chairman); **Professor Carl Borrebaeck,** Lund University; **Christian Vinding Thomsen**, Partner in Bech Bruun and **Thomas Feldthus**, vVD, CFO and co-founder of Saniona.

The Scientific Advisory Committee currently includes **Palle Christophersen**, CSO, Saniona A/S and **Susan Bates**, Director, Translational Cancer Medicine, Columbia University Medical Center.

RISK

An investment in Scandion Oncology A/S is associated with risks. Clinical studies are time and expense demanding and the results subject to uncertainty. Success in the initial phases of the development is not necessarily synonymous with success later on. The risk factors should be carefully scrutinized before an investment decision is made. It is not possible to quantify the significance of individual risk factor.

CONTACT

Nils Brünner, CEO
Mail: nb@scandiononcology.com
Tel; +45 26144708
www.scandiononcology.com